Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended ...

2 November 2026 · By · Wire by Fusion42

Published

2 November 2026

Topic

operational-macro

◆ Sectors

Healthtech Infrastructure

◆ Geography

United States

◆ Source

Read at desmoinesregister.com →

◆ Verified

Fusion42 · 2 November 2026 · Fusion42 review

DataMEDS AI's pharmacy arm Corexa Health has secured an agreement to commercially supply six peptides recommended by the FDA Pharmacy Compounding Advisory Committee under the new HHS Enforcement Discretion Policy, enabling compliant dispensing through a network of over 6,500 independent pharmacies starting November 2026.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.

◆ ◆ The Wire takeaway

You can now supply peptides to independent pharmacies within the new HHS enforcement framework, creating a regulated route to replace risky grey market products.

◆ Coverage

1 source · 2 Nov 2026

◆ Related on Wire

◆ Topics

Healthtech Infrastructurepeptidesfda-policycompounding-pharmacyhealthtechpharmaceutical-supply